We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

62 hedge funds and large institutions have $8.84M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more call options, than puts

Call options by funds: $963K | Put options by funds: $285K

13% less funds holding

Funds holding: 71 → 62 (-9)

20% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 15

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

55% less capital invested

Capital invested by funds: $19.8M → $8.84M (-$10.9M)

Holders
62
Holders Change
-9
Holders Change %
-12.68%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
15
Closed
17
Calls
$963K
Puts
$285K
Net Calls
+$678K
Net Calls Change
-$755K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$490K
2
VF
Virtu Financial
New York
+$130K
3
Renaissance Technologies
Renaissance Technologies
New York
+$79.6K
4
JP Morgan Chase
JP Morgan Chase
New York
+$73.8K
5
MCP
Mirador Capital Partners
California
+$38.2K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.27M
2
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
-$798K
3
DC
Davenport & Co
Virginia
-$173K
4
Bank of America
Bank of America
North Carolina
-$137K
5
TAM
Tocqueville Asset Management
New York
-$112K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$14K +$20.7K +2,440 New
Barclays
27
Barclays
United Kingdom
$13K -$5.87K -691 -22%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$12K – – –
Citadel Advisors
29
Citadel Advisors
Florida
$11K -$60.9K -7,161 -79%
SW
30
SteelPeak Wealth
California
$11K -$17K -2,000 -50%
JCP
31
JB Capital Partners
New York
$9K – – –
CG
32
Cutler Group
California
$8K – – –
Victory Capital Management
33
Victory Capital Management
Texas
$8K +$238 +28 +2%
WIM
34
Westside Investment Management
California
$7.23K – – –
BSW
35
Buckingham Strategic Wealth
Missouri
$7K – – –
PCS
36
Personal CFO Solutions
New Jersey
$6K – – –
HighTower Advisors
37
HighTower Advisors
Illinois
$6K +$2.55K +300 +39%
HF
38
HRT Financial
New York
$6K +$9.5K +1,118 New
PTP
39
Platform Technology Partners
New York
$5K – – –
SWM
40
Spire Wealth Management
Virginia
$5K +$7.37K +867 New
ARC
41
Advisor Resource Council
Texas
$4K -$5.66K -666 -50%
GG
42
Gofen & Glossberg
Illinois
$4K – – –
Simplex Trading
43
Simplex Trading
Illinois
$3K – – –
National Bank of Canada
44
National Bank of Canada
Quebec, Canada
$2K +$3.39K +399 New
HWA
45
HHM Wealth Advisors
Tennessee
$1K – – –
Northwestern Mutual Wealth Management
46
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
Wells Fargo
47
Wells Fargo
California
$1K +$26 +3 +1%
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$839 – – –
LTI
49
Laffer Tengler Investments
Tennessee
$86 – – –
Fuller & Thaler Asset Management
50
Fuller & Thaler Asset Management
California
– -$798K -71,991 Closed
1
2
3

EVFM Hedge Fund Activity: Q4 2021 in Review

62 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2021, worth a combined $8.84M — down 55% from $19.8M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of EVFM and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 12 added.

The largest buyer was GSA Capital Partners, adding an estimated $490K. The largest seller was D.E. Shaw & Co, cutting an estimated $1.27M.

  • 62 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2021, down from 71 in Q3 2021.
  • Funds reported $8.84M of Evofem Biosciences, Inc. Common Stock stock for Q4 2021, down 55% quarter-over-quarter.
  • 8 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2021 and 17 closed out, a net change of -9 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2021 was GSA Capital Partners, an estimated $490K added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2021 was D.E. Shaw & Co, an estimated $1.27M sold.

Based on aggregated 13F filings for Q4 2021.